Trius raising funds for antibacterial work; Vanda touts preliminary data;

@FierceBiotech: A future threat to Provenge? Researchers target multiple tumors (prostate, lung, others) in new cancer vaccine study. Article | Follow @FierceBiotech

@JohnCFierce: Interesting note: Abingworth, a major Avila investor, also cashed out of Intellikine ($310M) in Dec. For VCs, M&A is key this year. | Follow @JohnCFierce

@MarkHFierce: Obama is pushing (again) for more funding for basic research. Is anybody going to listen this time? More | Follow @MarkHFierce

> The antibacterial drug developer Trius Therapeutics ($TSRX) is offering 8.6 million shares at a discount. Report

> Vanda Pharmaceuticals says its reaped some early efficacy data on four patients enrolled in its Phase III study for tasimelteon, a treatment designed to reset the body's biological clock. Release

Pharma News

@FiercePharma: $BMY earnings might have disappointed analysts--and Plavix is faltering--but newer meds grew--Bloomberg. Article | Follow @FiercePharma

> Abbott's round of 700 layoffs doesn't spare pharma. Story

> Ranbaxy faces 'groundbreaking' oversight with DoJ settlement. Item

> Bristol-Myers' Q4 shows growth in newer products. Report

Vaccines News

> Common chemicals threaten childhood vaccines. Story

> Researchers target multiple tumors in new cancer vaccine study. More

> Nanoparticles hijack immune response. Article

> Late-stage Galena vax offers hope for breast cancer patients. Story

Pharma Manufacturing News

> Owner arrested in Pakistani drug deaths cites Big Pharma conspiracy. Article

> Abbott includes manufacturing in 700 job cuts. News

> Warnings analysis spotlights analytics weakness. Story

> Merck 'program of projects' earns facility award. More

And Finally... A new study from Johns Hopkins shows that a doctor's weight could influence how they diagnose obesity in their patients. Release

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.